Soluble ST2 levels for predicting the presence and severity of metabolic syndrome

Xiao Zong1,2,*, Qin Fan1,2,*, Hang Zhang1,2,*, Qian Yang1,2, Hongyang Xie1,2, Qiujing Chen1,2, Ruiyan Zhang1 and Rong Tao1

1Department of Vascular & Cardiology, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai, China
2Institution of Cardiovascular Diseases, Shanghai jiao Tong University School of Medicine, Shanghai, China

Correspondence should be addressed to R Tao: rongtao@hotmail.com

*(X Zong, Q Fan and H Zhang contributed equally to this work)

Abstract

To explore the relationship between soluble ST2 (sST2) and metabolic syndrome (MetS) and determine whether sST2 levels can predict the presence and severity of MetS. We evaluated 550 consecutive subjects (58.91 ± 9.69 years, 50% male) with or without MetS from the Department of Vascular & Cardiology, Shanghai jiao Tong University-Affiliated Ruijin Hospital. Serum sST2 concentrations were measured. The participants were divided into three groups according to the sST2 tertiles. Univariate and multivariable logistic regression models were used to evaluate the association between serum sST2 concentrations and the presence of MetS. Serum sST2 concentrations were significantly higher in the MetS group than in those in the no MetS group (14.80 ± 7.01 vs 11.58 ± 6.41 ng/mL, \( P < 0.01 \)). Subjects with more MetS components showed higher levels of sST2. sST2 was associated with the occurrence of MetS after multivariable adjustment as a continuous log-transformed variable (per 1 SD, odds ratio (OR): 1.42, 95% CI: 1.13–1.80, \( P < 0.01 \)). Subgroup analysis showed that individuals with MetS have significantly higher levels of sST2 than those without MetS regardless of sex and age. High serum sST2 levels were significantly and independently associated with the presence and severity of MetS. Thus, sST2 levels may be a novel biomarker and clinical predictor of MetS.

Introduction

Metabolic syndrome (MetS) is a constellation of metabolic abnormalities comprising central obesity, hypertension, diabetes mellitus (DM) or hyperglycemia, high triglyceride (TG) levels, and low levels of high-density lipoprotein cholesterol (HDL-C) (1). The prevalence rate of MetS has markedly increased over the past decades due to obesity resulting from widespread overnutrition and an inactive lifestyle. The International Diabetes Federation estimates that MetS affects one-quarter of the world’s adult population (2). Therefore, it has gradually become a major public health concern worldwide. MetS is also considered a chronic systemic inflammatory state and the main promoter of cardiovascular disease and multi-organ dysfunction (3, 4). However, there is limited data for predicting MetS and evaluating its severity.

Growth stimulation expressed gene 2 protein (ST2) was first discovered in 1989 (5) and its only known ligand is IL-33 (6). Two main isoforms of ST2 were found: a transmembrane full-length form (ST2L) and a soluble, secreted form (sST2) (7). The binding of ST2L and IL33 plays a protective role in cardiac stress (8, 9). However, sST2 acts as a decoy receptor of IL33 and inhibits IL33-ST2 signaling. sST2 has been identified as a promising biomarker of cardiovascular disease, especially in heart failure (10, 11, 12, 13).
Materials and methods

Study design and population

This cross-sectional study evaluated 550 consecutive subjects from the Department of Vascular & Cardiology, Shanghai Jiao Tong University-Affiliated Ruijin Hospital, Shanghai, China. The inclusion criteria were older than 18 years with no coronary heart disease, heart failure, malignant tumor and autoimmune disease. The diagnosis of MetS was made after enrollment.

This study was approved by the institutional review committee of Ruijin Hospital (Ethics Committee reference number: 2016-019), and was conducted in accordance with the principles of the Helsinki Declaration. Written informed consent was obtained from all the participants in this study.

Data collection and measures

Baseline data, including medical history, health status, and family history, were obtained via face-to-face interviews. Height, weight, and waist circumference were measured using standard measurements. BMI was calculated using weight and height (kg/m²). Blood pressure was measured in the left arm using a calibrated aneroid sphygmomanometer, with the participant in a seated position after at least 5 min of rest.

Peripheral venous blood samples were collected and centrifuged at 1500 g at 4°C for 15 min. The serum obtained by centrifugation was rapidly stored at −80°C. Echocardiography was conducted within 1 week from the collection of peripheral venous blood samples. Fasting plasma glucose, total cholesterol, TG, HDL-C, low-density lipoprotein cholesterol (LDL-C), and other routine biochemical parameters were measured using an automatic analyzer. Serum sST2 was measured using the venous serum samples via an ELISA Kit (DST200, R&D) according to the manufacturer’s protocol.

Echocardiography

All subjects underwent two-dimensional transthoracic echocardiography. After finding the standard long axial section of the left ventricle, M-mode echocardiography was used to measure the left ventricular end systolic diameter, left ventricular end diastolic diameter, left atrial diameter (LAD), aortic dimension, interventricular septal thickness (IVT), and left ventricular posterior wall thickness (LVPWT). Simpson’s biplane method was used to measure left ventricular ejection fraction (LVEF).

Definition of MetS

The most widely accepted and clinically used definitions of MetS were established by the World Health Organization, National Cholesterol Education Program – Third Adult Treatment Panel (NCEP-ATPIII), and International Diabetes Federation. These three definitions differ only in detail. Here, we used the definition of NCEP-ATPIII for MetS, and waist circumference (WC) was adopted as a factor that is more suitable for the Chinese population. Criteria of MetS were as follows (15): (i) Central obesity: WC ≥ 90 cm in men or ≥ 80 cm in women; (ii) TG ≥ 1.7 mmol/L or treatment of this lipid abnormality; (iii) HDL-C < 1.03 mmol/L in men or < 1.30 mmol/L in women; (iv) blood pressure ≥ 130/85 mmHg or taking antihypertensive medications; and (v) fasting blood glucose ≥ 5.6 mmol/L, previously diagnosed type 2 DM, or taking antidiabetic medications including oral antidiabetic agents or insulin. (Criteria for type 2 DM: symptoms of diabetes + plasma glucose at any time ≥ 11.1 mmol/L or fasting plasma glucose ≥ 7.0 mmol/L or oral glucose tolerance test 2-h ≥ 11.1 mmol/L.)

Specifically, subjects meeting three or more of the five criteria above were considered to have MetS while those meeting one or two or zero of the five criteria could be excluded from MetS diagnosis.

Statistical analyses

Continuous variables were presented as mean ± s.d., whereas categorical variables were summarized as numbers and percentages. Variables with a skewed distribution were log-transformed to make them fit a normal distribution. Independent Student’s t-test, one-way ANOVA test, the chi-square test and linear trend test were used to evaluate the differences among groups, as appropriate. Pearson correlation analysis was used to describe the correlations between sST2 levels and metabolic features.

Increasing evidence shows that MetS shares a similar pathophysiological process with cardiovascular disease, including inflammation, hypertension, atherosclerosis, and insulin resistance (14). Thus, it is reasonable to consider that sST2 levels may be able to indicate early microenvironment abnormalities, such as MetS, that predate the onset of cardiovascular disease. Therefore, the present study aimed to explore the diagnostic and predictive value of sST2 levels for the occurrence of MetS and its severity.

https://ec.bioscientifica.com
https://doi.org/10.1530/EC-20-0645
© 2021 The authors Published by Bioscientifica Ltd
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Subsequently, univariate and multivariable logistic regression models were used to evaluate the association between serum sST2 levels and the risk for MetS. For these models, we used (i) log-transformed sST2 level as a continuous variable analyzed per SD and (ii) tertiles of sST2 levels analyzed both as an ordinal variable and as categorical data. Subgroup analyses by age (≥60/ <60 years) and sex (male/female) were also conducted. All statistical tests were performed using IBM SPSS Statistics 22.0. A two-sided P-value of < 0.05 was considered statistically significant.

Results

Subject characteristics

Overall, 275 (50.0%) subjects were male. The mean age was 58.91 ± 9.69 years, and the mean sST2 level was 12.88 ± 6.84 ng/mL. The baseline subject characteristics are shown in Table 1 by tertiles of serum sST2 concentrations. There were trends across tertiles of higher levels of BMI, WC, systolic blood pressure, fasting glucose, glycosylated hemoglobin (HbA1c), and triglyceride levels, along with lower levels of HDL. In addition, subjects with higher sST2 levels had higher concentrations of white blood count, high-sensitivity C-reactive protein (hsCRP), and NT-proBNP, along with poorer liver and renal function. Among the subjects in the highest and lowest tertile of sST2, 59.0 and 43.2% were male, respectively. The LDL-C and LVEF levels were not significantly different among the patients in the three tertiles.

sST2 levels were associated with the presence of MetS

sST2 concentrations were significantly higher in the MetS group than that in the no MetS group (14.80 ± 7.01 vs 11.58 ± 6.41 ng/mL, P < 0.01, Fig. 1A). Subjects with higher MetS scores (i.e. more components of MetS) showed higher levels of sST2 (Fig. 1B). As shown in Table 2, sST2 was associated with the presence of MetS after multivariable adjustment as a continuous log-transformed variable (per 1 SD, odds ratio (OR): 1.42, 95% CI: 1.13–1.80, P < 0.01). Analysis of the tertiles of sST2 also showed that the adjusted risk of MetS was higher in subjects in the highest tertile than that in the subjects in the lowest tertile (OR: 2.52, 95% CI: 1.45–4.39, P < 0.01, Ptrend < 0.01).

Subgroup analysis by age and sex

Subgroup analysis showed that in both men and women and in subjects aged <60 years and ≥60 years, MetS patients exhibited significantly higher levels of sST2 than those without MetS (Fig. 1C). Univariate and multivariable logistic regression analyses of the relationship between sST2 and MetS according to age and sex are shown in Table 3. After full adjustment, patients in the highest group of serum sST2 levels had significantly higher risk than those in the lowest group regardless of age and sex. Furthermore, as a continuous variable, sST2 retained significant predictive value particularly in the older group (adjusted OR: 1.83, 95% CI: 1.31–2.56, P < 0.01) and in men (adjusted OR: 1.80, 95% CI: 1.29–2.49, P < 0.01). This indicated that serum sST2 levels were independently associated with the risk for MetS in all subjects, especially in men and in subjects older than 60 years.

Relationship between sST2 and MetS components

We further analyzed the relationship between sST2 and each MetS component. Subjects with central obesity, hypertension, DM or hyperglycemia, hypertriglyceridemia, and lower HDL had significantly higher concentrations of serum sST2 than those without it (Fig. 2A). After adjustment for the full model including age, sex, BMI, alcohol use, smoking, and levels of creatinine, LDL-C, hsCRP, and NT-proBNP (model 3), the association between sST2 and each specific disease remained statistically significant (Fig. 2B and C). The ORs corresponding to a 1 s.d. increase of log-transformed sST2 level for the presence of hypertension, DM, hypertriglyceridemia, and lower HDL were 1.71 (95% CI: 1.36–2.15, P < 0.01), 1.41 (95% CI: 1.15–1.73, P < 0.01), 1.27 (95% CI: 1.04–1.56, P < 0.02), and 1.23 (95% CI: 1.01–1.50, P = 0.04), respectively. Subjects in the highest level of sST2 had a significantly higher risk of meeting each diagnostic criterion of MetS than those in the lowest group, especially the blood pressure criteria (OR: 4.06, 95% CI: 2.39–6.92, P < 0.01).

Discussion

MetS shares a similar pathophysiological process with cardiovascular disease, and thus it is reasonable to consider that sST2 levels, as a novel biomarker of cardiovascular disease, may also be a biomarker of MetS. In this study, serum sST2 levels increased with an increase in the number of metabolic abnormalities.
Table 1  Baseline characteristics of all subjected divided by serum levels of ST2.

| Number | Age, years | Male, sex | BMI (kg/m²) | Waist circumference (cm) | Current smoking | Alcohol use | Systolic blood pressure (mmHg) | Diastolic blood pressure (mmHg) | Family history | Medical history | Laboratory measurements | Echocardiography parameters | Univariate and multivariable logistic regression analyses |
|--------|------------|-----------|-------------|--------------------------|----------------|------------|-------------------------------|-------------------------------|----------------|----------------|------------------------|-----------------------------|--------------------------------------------------|
|        | < 8.97 ng/mL | 8.97-13.70 ng/mL | ≥13.70 ng/mL | P value | for linear trend |
| 183    | 56.74 ± 9.00 | 60.08 ± 8.91 | 59.89 ± 10.74 | <0.01 | <0.01 |
| 184    | 79 (43.2) | 88 (47.8) | 108 (59.0) | 0.01 | <0.01 |
| 13.70 ng/mL | 23.42 ± 2.95 | 24.28 ± 3.64 | 24.67 ± 3.73 | <0.01 | <0.01 |
| 24.28 ± 3.64 | 80.00 ± 9.94 | 82.60 ± 11.95 | 84.55 ± 13.20 | <0.01 | <0.01 |
| (16.4) | 50 (27.6) | 52 (28.1) | 55 (29.5) | 0.01 | <0.01 |
| 19 (10.4) | 28 (15.2) | 28 (15.3) | 54 (29.5) | 0.01 | <0.01 |
| 125.25 ± 15.98 | 129.67 ± 18.55 | 134.49 ± 18.36 | <0.01 | <0.01 |
| 75.31 ± 10.29 | 75.10 ± 11.51 | 76.52 ± 12.21 | 0.44 | 0.31 |
| 16 (8.7) | 13 (7.1) | 14 (7.7) | 0.19 | 0.70 |
| 16 (8.7) | 13 (7.1) | 14 (7.7) | 0.19 | 0.70 |
| 125.25 ± 15.98 | 129.67 ± 18.55 | 134.49 ± 18.36 | <0.01 | <0.01 |
| 75.31 ± 10.29 | 75.10 ± 11.51 | 76.52 ± 12.21 | 0.44 | 0.31 |
| 16 (8.7) | 13 (7.1) | 14 (7.7) | 0.19 | 0.70 |
| 16 (8.7) | 13 (7.1) | 14 (7.7) | 0.19 | 0.70 |
| 125.25 ± 15.98 | 129.67 ± 18.55 | 134.49 ± 18.36 | <0.01 | <0.01 |
| 75.31 ± 10.29 | 75.10 ± 11.51 | 76.52 ± 12.21 | 0.44 | 0.31 |
| 16 (8.7) | 13 (7.1) | 14 (7.7) | 0.19 | 0.70 |
| 16 (8.7) | 13 (7.1) | 14 (7.7) | 0.19 | 0.70 |
| 125.25 ± 15.98 | 129.67 ± 18.55 | 134.49 ± 18.36 | <0.01 | <0.01 |
| 75.31 ± 10.29 | 75.10 ± 11.51 | 76.52 ± 12.21 | 0.44 | 0.31 |
| 16 (8.7) | 13 (7.1) | 14 (7.7) | 0.19 | 0.70 |
| 16 (8.7) | 13 (7.1) | 14 (7.7) | 0.19 | 0.70 |
| 125.25 ± 15.98 | 129.67 ± 18.55 | 134.49 ± 18.36 | <0.01 | <0.01 |
| 75.31 ± 10.29 | 75.10 ± 11.51 | 76.52 ± 12.21 | 0.44 | 0.31 |
| 16 (8.7) | 13 (7.1) | 14 (7.7) | 0.19 | 0.70 |
| 16 (8.7) | 13 (7.1) | 14 (7.7) | 0.19 | 0.70 |

Data are presented as mean ± s.d. or n (%).

ACEI, angiotensin-converting enzyme inhibitors; ALT, alanine aminotransferase; ARB, angiotensin receptor blockers; CCB, calcium channel blockers; eGFR, estimated glomerular filtration; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; hsCRP, high sensitivity C reactive protein; IVT, interventricular septal thickness; LAD, left anterior descending coronary artery; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter; LVESD, left ventricular end systolic diameter; LVPWT, left ventricular posterior wall thickness; NTproBNP, N-terminal pro-brain natriuretic peptide; WBC, white blood cell.

Univariate and multivariable logistic regression analyses demonstrated that high ST2 level was an independent risk factor for the presence of MetS, especially in men and in subjects older than 60 years. Thus, serum ST2 may be a biomarker for MetS. To our best knowledge, this study is the first to provide evidence on a correlation between serum ST2 levels and the presence and severity of MetS in the Chinese population.

Several studies have demonstrated that a continuous low-grade chronic systemic inflammatory state is an important pathophysiological feature of MetS, and some inflammatory factors are associated with it (16). Soluble ST2, as an important serum biomarker, has been shown to be involved in some inflammation-associated diseases. For example, during the acute exacerbation of idiopathic pulmonary fibrosis with the infiltration of inflammatory cells in the lungs, the serum levels of ST2 significantly increased with the development of inflammation (17). Serum ST2 levels were also found to be higher in asthma, which is a typical inflammatory disease, and was strongly
Table 2

| Variable                        | Unadjusted OR | P value | Adjusted OR for model 1 | P value | Adjusted OR for model 2 | P value |
|---------------------------------|---------------|---------|--------------------------|---------|--------------------------|---------|
| Log ST2 per s.d.                | 1.75 (1.45–2.11) | <0.01  | 1.67 (1.35–2.07)        | <0.01  | 1.42 (1.13–1.80)        | <0.01  |
| ST2 tertiles                    |               |         |                          |         |                          |         |
| Tertile 1                       | 2.01 (1.61–2.51) | <0.01  | 1.88 (1.47–2.42)        | <0.01  | 1.58 (1.20–2.08)        | <0.01  |
| Tertile 3                       | 2.53 (1.61–3.97) | <0.01  | 2.23 (1.35–3.68)        | <0.01  | 1.68 (0.98–2.89)        | 0.06    |
| Tertile 4                       | 4.14 (2.63–6.49) | <0.01  | 3.58 (2.16–5.93)        | <0.01  | 2.52 (1.45–4.39)        | <0.01  |

Model 1: adjusted for age, gender and BMI. Model 2: adjusted for age, gender, BMI, alcohol use, smoke, creatinine, LDL-C, hsCRP and NTproBNP. Continuous variables were entered per 1 SD.

hsCRP, high sensitivity C reactive protein; LDL-C, low-density lipoprotein cholesterol; MetS, metabolic syndrome; NTproBNP, N-terminal pro-brain natriuretic peptide; OR, odds ratio.

Thus, we speculated that sST2 could indicate the inflammation level in patients with MetS, in many ways influencing multiple aspects. Further, we found high sST2 levels in patients with central obesity. Monocyte-derived macrophages residing in adipose tissue can secrete various proinflammatory factors such as tumor necrosis factor-α, interleukin-6, and interleukin-1. Therefore, obesity itself is a state of inflammation, which may be reflected or influenced by sST2. Moreover, hypertension, DM, and dyslipidemia are also regarded as chronic inflammation processes involving multiple organs (20, 21, 22). ST2 itself may participate in the pathophysiological process of each component of MetS by affecting the inflammatory and immune response, thus taking part in the occurrence and development of MetS as well as reflecting its severity.

It is generally believed that ST2 functions through the IL33-ST2 axis, that is, it binds to IL33 as bait and blocks IL33 activation of downstream signaling pathways. However, whether the IL33-ST2 axis confers pro- or anti-inflammation effects depends on the disease type. For example, in an ovalbumin-induced murine model of asthma, ST2-deficient mice developed attenuated airway inflammation and IL-5 production. Meanwhile, IL-33 administration exacerbated airway inflammation in wild-type mice (23). In another inflammation-associated disease, IL-33 treatment lowered the development of atherosclerosis and macrophage accumulation in ApoE−/− mice fed with a high-fat diet. This effect can be blocked by sST2, thus leading to a larger atherosclerosis plaque (24). This characteristic may be due to the activation of different downstream pathways. The inflammatory process in MetS involves multiple organs and systems. Therefore, the role of sST2 in MetS may not be simply summarized as proinflammatory or anti-inflammatory, despite its relationship with disease severity. As such, further studies are warranted.

Each component of MetS has the potential to affect the endothelium and cause vascular dysfunction or disrupt vascular homeostasis. In turn, endothelial
dysfunction can aggravate MetS. Vascular dysfunction is a key contributor to the pathogenesis of MetS. Our research shows that sST2 is strongly correlated with high systolic blood pressure but not diastolic blood pressure, consistent with the findings of a previous study (25). This result indicates that sST2 may correlate with vascular stiffness and compliance. Both ST2 and IL-33 are expressed and act in human endothelial cells (26, 27). As such, sST2, which is derived from ST2 and interacts with IL-33, may also play an important role in vascular biology.

Furthermore, the excessive production of reactive oxygen species (ROS) is another reason for endothelial dysfunction and metabolic disorders in MetS (28, 29). Fat cell and macrophage accumulation can increase ROS production and fatty acid concentration during hyperlipidemia. This in turn inhibits the efficiency of oxidative phosphorylation, and the production of ROS also increases sharply. Excessive ROS can oxidize various lipid components, such as oxidized LDL, which plays an important role in endothelial dysfunction and the development of MetS. Studies have shown that ROS can activate the IL33/ST2 axis and promote the release of IL33, which can in turn inhibit ROS production (8, 30).

Therefore, the ST2-IL33 axis plays a protective role in endothelial dysfunction caused by oxidative stress, while sST2 functions in the opposite direction.

Abnormal glucose and lipid metabolism is an important characteristic of MetS. Studies have shown that sST2 is associated with glucose and lipid metabolism. In type 2 diabetes patients with normal blood glucose tolerance, circulating sST2 levels were significantly higher and were significantly associated with fasting blood glucose and HbA1c (31). Bariatric surgery in severely obese diabetes patients improves metabolic status, and we also observed worse liver function and lipid metabolism markers (32). In line with these findings, we found that sST2 is correlated with DM and dyslipidemia. The liver is the main organ for glucolipid metabolism, and we also observed worse liver function in patients with the highest sST2 tertile.

In line with these findings, we found that sST2 is correlated with DM and dyslipidemia. The liver is the main organ for glucolipid metabolism, and we also observed worse liver function in patients with the highest sST2 tertile. However, the role of the IL33-ST2 pathway in liver metabolism remains controversial (33, 34), and the involvement of sST2 in glucose and lipid metabolism abnormalities needs to be further studied.

On the other hand, our present study demonstrated that sST2 levels were associated with cardiac hypertrophy,
as indicated by the relationship of sST2 with LAD, IVT and LVPWT, which is in accordance with another study of patients with MetS (35). However, cardiac hypertrophy may only be a secondary outcome of hypertension and inflammation, so evidence for a direct link between sST2 and cardiac hypertrophy is lacking.

Limitations

This study has some limitations. First, it is a small-scale and single-center study. Therefore, we could not completely avoid the influence of confounding factors on our findings. Second, we did not detect the serum level of IL-33, and thus it is unclear whether sST2 functions through IL33. Third, because of the cross-sectional design, we cannot determine the causal relationship between MetS and sST2, thus needing further investigation, especially basic experiments. Moreover, studies with a larger sample size are needed to validate the diagnostic value of sST2 levels in MetS.

Conclusion

The present study found that high serum sST2 levels were significantly and independently associated with the presence and severity of MetS. Subjects with more MetS components showed higher levels of sST2. Thus, sST2 levels may be a novel biomarker of MetS.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This study was supported by the National Nature Science Foundation of China (81670352 and 81970327 to R T, 82000368 to Q F).

Acknowledgement

The authors would like to thank all the enrolled subjects for their patience and understanding.
1 Eckel RH, Grundy SM & Zimmet PZ. The metabolic syndrome. 
Lancet 2005 365 1415–1428. (https://doi.org/10.1016/S0140-6736(05)66378-7)

2 Alberti G, Zimmet P & Shaw J. Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. 
Diabetes Medicine 2006 23 469–480. (http://doi.org/10.10111/j.1464-5941.2006.01858.x)

3 Lin YH, Zhang RC, Hou LB, Wang KJ, Ye ZN, Huang T, Zhang J, Chen X & Kang JS. Distribution and clinical association of plasma soluble ST2 during the development of type 2 diabetes. 
Diabetes Research and Clinical Practice 2016 118 140–145. (https://doi.org/10.1016/j.diabres.2016.06.006)

4 Malik S, Wong ND, Franklin SS, Kamath TV, L’Italien GJ, Pito JR & Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. 
Circulation 2004 110 1245–1250. (https://doi.org/10.1161/01.CIR.0000140467.20060.0E)

5 Klemenz R, Hoffmann S & Werenskiold AK. Serum- and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen. 
PNAS 1989 86 5708–5712. (https://doi.org/10.1073/pnas.86.15.5708)

6 Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zuraswki G, Moshrefi M, Qin J, Li X, McKenzie AN & Lee RT. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. 
Circulation: Heart Failure 2009 2 684–691. (https://doi.org/10.1161/CIRCHEARTFAILURE.109.873240)

7 Weinberg EO, Shimpo M, Hurwitz S, Tominaiga S & Rouleau JL. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. 
Circulation 2003 107 721–726. (https://doi.org/10.1161/01.cir.0000047247.66749.fe)

8 Almo A, Vergaro G, Passino C, Ripoli A, Ky B, Miller WL, Bayes-Genis A, Anand I, Januzzi Jr JL & Emdin M. Prognostic value of soluble ST2 protein in patients with heart failure. 
JACC: Heart Failure 2017 5 5708–5712. (https://doi.org/10.1016/j.jchf.2016.09.010)

9 Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith Jr SC, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. 
Circulation 2005 112 2735–2752. (https://doi.org/10.1161/CIRCULATIONAHA.105.169404)

10 Watanabe M, Nakamoto K, Inui T, Sada M, Honda K, Tamura M, Ogawa Y, Yokoyama T, Saraya T, Kurali D, et al. Serum sST2 levels predict severe exacerbation of asthma. 
Respiratory Research 2018 19 169. (https://doi.org/10.1186/s12931-018-0872-2)

11 Griesenauer B & Pazeszy S. The ST2/IL-33 axis in immune cells during inflammatory diseases. Frontier in Immunology 2017 8 475. (https://doi.org/10.3389/fimmu.2017.00475)

12 McCarthy CG, Goulopoulos S & Webb RC. Paying the toll for inflammation. 
Hypertension 2019 73 514–521. (https://doi.org/10.1161/HYPERTENSIONAHA.118.11782)

13 Li J, Pimentel N, Goulopoulou S & Webb RC. Serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. 
Chest 2003 124 1206–1214. (https://doi.org/10.1378/chest.124.4.1206)

14 Kita H & O’Grady SM. Oxidative stress serves as a key checkpoint in the development of type 2 diabetes mellitus. 
Diabetes Medicine 2004 21 469–480. (https://doi.org/10.1002/dia.2319)

15 Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith Jr SC, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. 
Circulation 2005 112 2735–2752. (https://doi.org/10.1161/CIRCULATIONAHA.105.169404)

16 Sutherland JP, Mckinley B & Eckel RH. The metabolic syndrome and inflammation. 
Metabolic Syndrome and Related Disorders 2004 2 82–104. (https://doi.org/10.1098/met.2004.2.82)

17 Tajima S, Oshikawa K, Tominaga S & Sugiyama Y. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. 
Chest 2003 124 1206–1214. (https://doi.org/10.1378/chest.124.4.1206)

18 McCarty CG, Goulopoulos S & Webb RC. Paying the toll for inflammation. 
Hypertension 2019 73 514–521. (https://doi.org/10.1161/HYPERTENSIONAHA.118.11782)

19 Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith Jr SC, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. 
Circulation 2005 112 2735–2752. (https://doi.org/10.1161/CIRCULATIONAHA.105.169404)

20 Griesenauer B & Pazeszy S. The ST2/IL-33 axis in immune cells during inflammatory diseases. Frontier in Immunology 2017 8 475. (https://doi.org/10.3389/fimmu.2017.00475)
a biomarker for cardiovascular mortality related to abnormal glucose metabolism in high-risk subjects. *Acta Diabetologica* 2019 56 273–280. (https://doi.org/10.1007/s00592-018-1230-z)

32 Demyanets S, Kaun C, Kaider A, Speidl W, Prager M, Oravec S, Hohensinner P, Wojta J & Rega-Kaun G. The pro-inflammatory marker soluble suppression of tumorigenicity-2 (ST2) is reduced especially in diabetic morbidly obese patients undergoing bariatric surgery. *Cardiovascular Diabetology* 2020 19 26. (https://doi.org/10.1186/s12933-020-01001-y)

33 Pejnovic N, Jefic I, Jovicic N, Arsenijevic N & Lukic ML. Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis. *World Journal of Gastroenterology* 2016 22 9706–9717. (https://doi.org/10.3748/wjg.v22.i44.9706)

34 Gao Y, Liu Y, Yang M, Guo X, Zhang M, Li H, Li J & Zhao J. IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis. *Oncotarget* 2016 7 33649–33661. (https://doi.org/10.18632/oncotarget.9259)

35 Celic V, Majstorovic A, Pencic-Popovic B, Sljivic A, Lopez-Andres N, Roy I, Escribano E, Beunza M, Floridi F, et al. Soluble ST2 levels and left ventricular structure and function in patients with metabolic syndrome. *Annals of Laboratory Medicine* 2016 36 542–549. (https://doi.org/10.3343/alm.2016.36.6.542)

Received in final form 22 December 2020
Accepted 10 February 2021
Accepted Manuscript published online 19 February 2021